Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Guidance and Visibility -- Ignore unavailable to you. Want to Upgrade?

To: CRUZ who wrote (98691)	11/16/2003 5:43:45 PM
From: Findit	Respond to of 208838

CRUZ here is 'supposedly' what the Clandra report had to say about CRDM. Got this from the CRDM Yahoo board. 'Cardima: In our latest text alerts, I also gave the audience a headsup about a medical-device developer, Cardima (CRDM). Once again, this is a company whose shares I own, but they are risky. I have no intention of selling them anytime soon, and my purchase price is at current levels of around $1.13. They are not suitable for The Recommended List because of their intensely speculative nature. But in coming weeks I may have a ground-breaking interview with an influential fund manager on another biomedical company that could make the list. If I decide to place that company on The Recommended List, I will wait a week before purchasing shares. My thesis on Cardima, one that I share with Banister, is that biomedical companies, especially in the medical devices area, may soon see their equity values rise ahead of Food & Drug Administration advisory panel hearings. This does not sound ground-breaking for the very reason that such hearings, or anticipation of such hearings, used to send individual biotech company shares to the moon several years ago (and still occasionally do). Hohum, been there, right? And FDA advisory recommendations are not binding on the top gun (or is it needle?) who signs the docs at the FDA. Still, those who read the financial news pages, among them The New York Times, know that medical-device makers are making headlines as baby-boomers demand more and more in the way of breakthrough health care. Cardima has been working for 20 years on what are called atrial fibrillation devices for the heart. Banister owns the stock for himself and clients. One can compare Cardima to I-Flow (IFLO), which Banister says “based for a significant period and finally got some FDA approvals and then Medicare approvals. The stock went from $1.40 a year ago to $14 today and growing.” Cardima could enjoy a rise in value if an FDA advisory panel approves their second application for the fibrillator. The company had initial approval already earlier this year for another procedure in Europe and Canada. “Approval of this second procedure (installation of an implantable device) will surely carry the stock to 52 week highs above $2.40, where it touched in May of this year,” says Banister. “The company is on hold in signing on a major marketing partner pending the FDA advisory panel update.” By the way, Cardima went to the FDA panel in May and mostly liked what it saw of the fibrillator data, but wanted more procedures done to complete the data.' Jim